• Explore /
  • Poster
  • / An intergroup phase III trial of ramucirumab plus irinotecan in third or more line beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial).

An intergroup phase III trial of ramucirumab plus irinotecan in third or more line beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial).

Abstract Poster

Authors

null

Daisuke Sakai

Osaka Gastrointestinal cancer chemotherapy Study Group (OGSG), Osaka, Japan

Daisuke Sakai , Narikazu Boku , Yasuhiro Kodera , Yoshito Komatsu , Masashi Fujii , Satoru Iwasa , Eiji Oki , Wasaburo Koizumi , Makio Gamoh , Kei Muro , Toshio Shimokawa , Taroh Satoh

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

UMIN000023065

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS4138)

DOI

10.1200/JCO.2018.36.15_suppl.TPS4138

Abstract #

TPS4138

Poster Bd #

323b

Abstract Disclosures

Similar Posters

First Author: Rui-hua Xu

First Author: Sylvie Lorenzen

First Author: Ken Shimada

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Real-world effectiveness of drugs newly approved in Japan on survival in patients with advanced gastric cancer.

Real-world effectiveness of drugs newly approved in Japan on survival in patients with advanced gastric cancer.

First Author: Toru Kadono